SLC5A2 and Stroke: So, looking at the ICERs (essentially the costs per event prevented) generated for the various CV events, it can be deduced that among the three commonly used SGLT-2 inhibitors available in India, dapagliflozin is the most cost-effective for the prevention of 3P-MACE (a composite of CV death, non-fatal stroke, and non-fatal MI), HHF, and MI while benefits for prevention of ACD and stroke are not so clear-cut because of discordant results from the real-world study and the CVOT.